A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

Publication | Open Access

DOI Full Paper Access

Citations

References

2019

Year

Christopher Geven, Alice Blet, Matthijs Kox, Oliver Hartmann, P. Scigalla, Jens Zimmermann, Gernot Marx, Pierre‐François Laterre, Alexandre Mebazaa, Peter Pickkers

BMJ Open

Abstract

References